Aclaris Therapeutics ACRS Cash Flow Statement (2014-2026)

NASDAQ ACRS
$4.13 -0.11 (-2.59%)
As of: Nov 10, 2026 · 1:26 PM EST
Reported Financials

Aclaris Therapeutics Quarterly Cash Flow Statement

Periods 49 quarters
Latest Sep 2026

Aclaris Therapeutics reported cash from operations of -$24.08M and free cash flow of -$24.09M for the quarter ended Sep 2026, down 120.3% year over year. This cash flow statement covers 49 quarters of results from Sep 2014 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-22.80M-18.79M-20.53M-19.95M-27.64M-28.16M-29.57M-29.26M-1.49M-16.94M-10.99M-7.59M-96.55M-15.09M-15.43M-14.61M-19.80M-19.82M-21.51M-18.51M
Depreciation and DepletionDep. & Depletion
0.20M0.20M0.20M0.20M0.10M0.20M0.20M0.20M0.20M0.20M0.20M0.20M0.10M0.10M0.10M0.10M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.20M0.21M0.21M0.19M0.19M0.20M0.22M0.22M0.23M0.24M0.24M0.18M0.14M0.13M0.11M0.11M0.10M0.10M0.11M0.10M
Share-based CompensationStock Comp.
3.85M2.35M3.69M4.19M4.81M6.81M6.52M5.95M1.27M2.09M2.90M3.00M2.86M3.54M3.06M2.86M2.93M3.20M2.67M3.02M
Asset Writedowns and ImpairmentWritedown
Cash from Restructuring
Other non-cash itemsOther Non-Cash
2.20M-1.20M-3.40M2.20M7.10M-0.80M-1.50M1.70M-19.67M2.80M0.20M0.80M85.61M0.30M1.50M0.10M0.40M0.30M-0.60M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.19M0.01M0.00M-0.04M-0.11M0.20M-0.26M-0.09M-0.05M0.08M-0.05M-3.73M8.57M-8.28M1.12M0.35M0.67M-0.74M1.22M2.91M
Change in InventoryChange Inventory
Change in Account PayablesChange Payables
2.36M-1.87M-2.42M1.96M2.69M-2.16M3.24M-2.15M-0.39M1.93M-3.54M0.39M-2.97M1.66M2.44M0.38M3.96M1.51M0.84M-6.47M
Change in Accrued ExpensesChange Accrued Exp.
2.54M-1.85M1.67M1.45M-0.68M-1.16M0.92M6.59M5.64M-12.91M-1.46M-1.15M11.57M-11.04M0.40M1.30M1.25M-3.03M-0.07M2.27M
Change in Other Operating AssetsOther Assets Change
5.61M-0.19M-1.12M-2.10M5.70M0.87M0.73M7.69M-7.98M-2.04M-0.27M-1.43M8.60M-8.21M1.18M
Change in Other Operating LiabilitiesOther Liabilities Change
-1.02M-0.83M-0.96M-0.72M-1.31M-0.85M-0.97M-0.99M
Other Working Capital ChangesOther WC Changes
-5.61M0.19M1.12M2.10M-5.70M-0.87M-0.73M-7.69M7.98M2.04M0.27M1.43M-9.62M7.38M-2.14M-0.72M-1.31M-0.85M-0.97M-0.99M
Cash from OperationsCash from Ops.
-17.08M-20.97M-19.67M-7.82M-19.12M-26.35M-20.65M-24.56M-6.76M-20.82M-12.32M22.00M-8.94M-13.06M-9.99M-10.93M-13.13M-18.15M-19.85M-24.08M
Investing Activities
Capital ExpendituresCapex
0.20M0.16M0.19M0.15M0.11M0.55M0.23M0.08M0.44M0.14M-0.01M0.04M0.02M0.02M0.02M0.01M0.06M0.01M
Change in Property, Plant and EquipmentChange in PP&E
-0.20M-0.16M-0.19M-0.15M-0.11M-0.55M-0.23M-0.08M-0.44M-0.14M0.01M-0.04M-0.02M-0.02M-0.02M-0.01M-0.06M-0.01M
Change in IntangiblesChange Intangibless
0.83M
Purchase of InvestmentsInvestments Purchased
35.29M14.56M70.54M33.63M46.02M28.52M89.99M17.16M14.34M70.43M10.00M19.93M5.20M4.61M51.67M8.93M53.21M
Sale and Maturity of InvestmentsInvestments Sold
26.32M44.65M49.50M35.00M48.83M54.88M70.56M49.78M7.99M16.97M34.53M17.13M17.51M29.99M25.00M19.05M15.00M20.75M19.25M20.00M
Cash from Investing ActivitiesCash from Investing
-9.18M29.93M-21.22M1.22M2.70M25.80M-19.66M32.53M7.55M16.83M-0.67M2.80M-88.72M19.12M5.05M13.83M10.37M-30.93M10.26M-33.22M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Net Long-Term Debt Issued (Repaid)Net LT Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
238.20M0.04M72.83M0.04M0.02M0.05M74.91M58.03M0.11M58.59M
Net Shares Issued and RepurchasedNet Shares Issued
238.20M0.04M72.83M0.04M0.02M0.05M74.91M58.03M0.11M58.59M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
238.20M0.04M72.83M0.04M0.02M0.05M74.91M58.03M0.11M58.59M
Other financing activities (as filed)
0.00M-0.01M-0.02M-0.01M-0.06M-0.01M-0.01M-0.33M-0.28M-0.01M-3.04M-2.53M-0.25M-0.02M-0.06M
Cash from Financing ActivitiesCash from Financing
0.00M0.03M72.81M-0.01M0.04M-0.09M0.05M-0.06M-0.01M0.02M74.58M-0.28M-0.01M-3.04M-2.53M57.78M0.09M58.53M
Additional items
Change in Cash
-26.25M8.99M31.92M-6.61M-16.38M-0.56M-13.57M7.89M0.84M-4.04M-13.01M24.82M-23.08M5.79M-4.96M-0.15M-5.30M8.70M-9.49M1.23M
Ending Cash Balance
27.35M36.34M68.26M61.65M45.28M44.72M31.15M39.04M39.88M35.84M22.83M47.65M24.57M30.36M25.40M25.26M19.96M28.66M19.17M20.39M
Free Cash FlowFCF
-17.28M-21.13M-19.85M-7.97M-19.22M-26.91M-20.89M-24.64M-7.20M-20.95M-12.31M22.00M-8.94M-13.10M-10.01M-10.96M-13.16M-18.16M-19.91M-24.09M
Net Cash FlowNCF
-26.25M8.99M31.92M-6.61M-16.38M-0.56M-40.32M7.89M0.84M-4.04M-13.01M24.82M-23.08M5.79M-4.96M-0.15M-5.30M8.70M-9.49M1.23M

Aclaris Therapeutics Cash Flow Statement API

Pull Aclaris Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ACRS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY